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Background

• Inconsistent antimicrobial dosing can lead to
suboptimal or supratherapeutic drug levels
contributing to antimicrobial resistance,
increased hospital costs, and adverse effects

• Despite incorporation of ceftriaxone dosing
within order sets, variability in dosing persists

• The goal of this quality improvement project
was to characterize ceftriaxone dosing based
on indication within the pediatric units at
Lehigh Valley Reilly Children’s Hospital

Methods

• Retrospective review of intravenous ceftriaxone
medication orders for pediatric patients was
performed between January 1, 2021 and
June 30, 2021
• Evaluations performed:

• Characterize ceftriaxone dosing based
on indication

• Examine the data for any trends in ceftriaxone
dosing associated with specific pediatric units
and indications
• Analyze order set utilization
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Results

characteristics of ceftriaxone orders
Patient age (years)

Median (IQR)

Children’s Emergency Room (ChER)
General Pediatric Unit (PEDS)

Pediatric Intensive Care Unit (PICU)
Operating Room (OR)

Order set utilization (n=90)
ChER

PEDS

Appendicitis

n (%)

189 (53.1)

127 (35.7)

Non-neutropenic
fever

■ ChER

6 (1.7)

Pneumonia

■ PICU

55 (61.1)

Respiratory
insufficiency

34 (9.6)

Urinary tract
infection

0

ceftriaxone indications
for orders placed in
peds n = 127
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1, 1%
6, 3%
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5, 15%

7, 5%
1, 1%

18, 10%
37, 20%

■ Appendicitis

■ Empiric meningitis

8, 6%
30, 24%

14, 7%

■ Fever, Sickle Cell

• Only 2 (2.2%) ceftriaxone doses prescribed using an
order set were non-standard, indicating that increased
order set utilization facilitates consistent ceftriaxone
dosing

• Future application of this data may include educating
providers on availability of clinical pathways and related
order sets and monitoring utilization

1, 3%

11, 9%

5, 3%
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42, 33%

53, 28%

19, 10%
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ceftriaxone indications
for orders placed in
picu n = 34

21, 16%

29, 15%

• Prescribed more commonly in the ChER (58%) and for
the following indications: appendicitis (n=8), empiric
meningitis (n=4), skin and soft tissue infection (n=5),
fever in patients with sickle cell disease (n=3), pneumonia
(n=1), respiratory insufficiency (n=1), sepsis (n=7), and
urinary tract infection (n=11)

■ PEDS

Sepsis

4 (4.4)

ceftriaxone indications
for orders placed in
cher n = 189

• Flat doses or doses equal to 75 mg/kg were most
commonly prescribed

Fever, Sickle Cell

0

OR

• Non-standard doses of ceftriaxone accounted for 14% of
total doses administered

Empiric
meningitis

31 (34.4)

PICU

• Empiric use of ceftriaxone in the management of
pneumonia and urinary tract infection did not follow
current clinical pathway recommendations

mean ceftriaxone dosing (mg/kg/day)
by indication and department

7 (11)

Department (n=356)

Conclusions

■ Non-neutropenic fever

4, 12%

1, 3%

6, 5%

■ Other

■ Pneumonia

7, 20%

■ Respiratory insufficiency

■ Sepsis

■ Urinary tract infection
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